about
Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study).Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials.HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience.MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis.Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study).Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer.Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosPooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and information.Development and 10-year history of a biosimilar: the example of Binocrit®.Extrapolation concept at work with biosimilar: a decade of experience in oncology.Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" ( 72 h): findings from the MONITOR-GCSF studyFebrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinatiPotential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 studyCorrection to: Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience GainedCritical Factors Shaping Strategy Development of an Innovative Medicine in OncologyEpoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocolsAsunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignanciesOverall survival and risk of second malignancies with cancer chemotherapy and G-CSF supportLongitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patientsInnovative oncology products: time to revisit the strategy development?Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF studySafety analysis of proposed pegfilgrastim biosimilar in Phase I and Phase III studiesThe evolution of value with filgrastim in oncologyMeta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancerFebrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphomaExtrapolation in Practice: Lessons from 10 Years with Biosimilar FilgrastimTreatment patterns and outcomes in patients with non-small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropaenia: Results from the MONITOR-GCSF studyEvaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patientsLong-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 studyEvolving Communication with Healthcare Professionals in the Pharmaceutical Space: Current Trends and Future Perspectives
P50
Q33599892-FCA744A7-3411-44EB-A212-4346D9F7AFAEQ37387974-17708647-7381-4157-A7D9-C88104191F16Q38689804-A2D8BB36-9F2E-435E-8693-ABC8131D3A80Q47094186-9E2E75DB-321A-4D53-82EA-2BDCB03187DCQ47419424-50520DE3-AE5B-476C-ABE9-AA15B549FA2FQ47951324-6D1ABD8B-BCD3-4CC9-B111-9889710A98BAQ49944003-CA2918C5-52B1-4F88-80EF-391F34D1B288Q50001689-3ED5F660-A39A-4A20-B1E0-6AB6D140C315Q50107702-C059AC97-AD8C-4872-852A-160921184E19Q50112937-4A2D2F10-7B5D-4A16-84F0-956604079ED5Q52840373-7964AB6B-85D9-4A51-9413-7A68F724F996Q53559623-24706785-2BF3-41B4-8E82-67221721A88CQ54959955-1F5D5A4C-CF8F-40F3-9E26-7BAB3D5BC56AQ55175552-6D763300-ABA8-43F5-8529-50195CA90F6EQ55177169-6B614323-166B-4EFC-9CDC-27AB71FE6CFBQ55384042-AC6790CC-E30E-494A-9ACA-9E23FC1A7E84Q57808962-A5A701C0-3D6F-42CF-A08D-7B6B90CB314BQ58700818-C351C172-5C73-47D2-9087-C089837EC6C3Q64061069-4B5FC8DF-01B5-4025-90C3-14E7C218C970Q87917344-B6277C90-CD07-44E7-A30F-339C30DE8168Q89928441-7992F054-12ED-43D3-A3F0-FC890A3C94ECQ90042104-E10EEB07-707F-4AEC-93EB-4BE1F83BEA23Q90354120-153F2E26-FA97-441A-8334-23D178583030Q90899039-E22DA68B-6AD2-44E7-A11E-00FD038B95B6Q91073649-80D5F4F4-FCF8-4FA4-A34C-12539A84201CQ91368844-2C599AC2-4A15-4D10-A154-49F42B13BCE5Q92079830-1F826719-7EFD-4214-AB8C-E2DD89D5F288Q92134934-DA28618A-4A2E-4AD5-B2DF-F1E7C8381308Q92137021-2349ECD2-07D3-426D-A322-CCEF9C7F65E4Q92211521-B06F7DFC-5652-488A-8A25-38E848801ACEQ92749324-A0A53871-AF69-4752-904D-7830A5C15E4CQ92805646-AB8D0550-41B6-4C76-A898-4381BFF9D40FQ92996072-562B8545-5D30-4A55-83D8-56FCD7E10F37Q95374573-CD94969C-2F44-4921-8AC8-805227729C96Q95428125-F41DE93E-1F41-414C-AE98-FA562248CE5DQ96583448-62733B3D-26A6-4BFA-9BAC-429C0EE4FFCF
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
Andriy Krendyukov
@ast
Andriy Krendyukov
@en
Andriy Krendyukov
@es
Andriy Krendyukov
@nl
type
label
Andriy Krendyukov
@ast
Andriy Krendyukov
@en
Andriy Krendyukov
@es
Andriy Krendyukov
@nl
prefLabel
Andriy Krendyukov
@ast
Andriy Krendyukov
@en
Andriy Krendyukov
@es
Andriy Krendyukov
@nl
P1153
57192815395
P31
P496
0000-0001-8557-1520